Peter Strumph

Peter Strumph is the current director at Amygdala Neurosciences. Prior to this, they served as the SVP Clinical and Technical Operations at Portola Pharmaceuticals from April 2013 to December 2015. From June 2010 to July 2012, they were the SVP Pharmaceutical Business Unit and Interim Chief Executive Officer at Codexis. From January 2016 to June 2021, they served as the Chief Executive Officer at Amygdala Neurosciences, Inc. From January 2007 to December 2009, they were the CEO at Nile Therapeutics. From January 1997 to December 2007, they were the SVP Operations at CV Therapeutics. From January 1993 to December 1997, they were the Manager Operations Planning at Biogen. Prior to that, they were a Business Analyst at Bio-Rad Laboratories from January 1991 to December 1993. Peter started their career as a Project Engineer at Bayer from January 1990 to December 1991.

Peter Strumph has received an MBA from The Wharton School in the field of finance and healthcare and a BAS from the University of Pennsylvania in system science and engineering.